Journals / Journal of Clinical and Analytical Medicine / 2016 / Cilt: 7 - Sayı: 4

Öncesi ve Sonrası: Türkiye'de Üçüncü Basamak Bir Hastanenin İlaç Harcamaları

Drug Expenditures of a Tertiary Hospital in Turkey: Before and After

Pages
494–496
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The number of patients referred to other tertiary referral hospitals in April 2012 and April 2013 was 132 and 91, respectively (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The budget allocated to health is increasing every year.
📊
Key Findings & Data:The data gained from the databases of the secondary referral hospital and the tertiary referral hospital was obtained in April of 2012 and April of 2013, respectively.
💡
Conclusion & Impact:The number of patients referred to other tertiary referral hospitals in April 2012 and April 2013 was 132 and 91, respectively (p
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: The budget allocated to health is increasing every year. Pharmacoeconomic research focuses on the costs and benefits of drug therapy. All conditions affecting costs should be evaluated; minimum cost and maximum effect must be targeted. In this study we aim to analyze the effects of the opening of a new tertiary health center on the costs of treatment and patient referral. Material and Method: The changes in drug costs and the number of patients in the emergency departments, pediatric clinics, pediatric intensive care units, neonatal intensive care units, delivery rooms, wards for risky pregnancies, and the septic services of a new tertiary referral hospital in Adiyaman city were compared with those of its former secondary referral hospital. The data gained from the databases of the secondary referral hospital and the tertiary referral hospital was obtained in April of 2012 and April of 2013, respectively. The data were analyzed retrospectively. Results: The total number of patients who were managed as outpatients or hospitalized in April 2012 and April 2013 was 10,838 and 11,066, respectively. The total cost of the drugs was 51,515 TL (approximately 25,000 USD) for April 2012 and 75,552 TL (approximately 37,000 USD) for April 2013. The number of patients referred to other tertiary referral hospitals in April 2012 and April 2013 was 132 and 91, respectively (p

Özet

Amaç: Sağlık için ayrılan bütçe her yıl artmaktadır. Farmako-ekonomik araştırmalar ilaç tedavilerinin maliyet ve faydalarına odaklanmaktadır. Maliyeti etkileyen her türlü durum değerlendirilmelidir; minimum maliyet maksimum etki amaçlanmaktadır. Bu çalışmada üçüncü basamak sağlık kuruluşunun açılmasının ilaç maliyeti ve hasta sevki üzerine etkisinin değerlendirilmesi amaçlandı. Gereç ve Yöntem: Adıyaman ilinde bir hastanenin üçüncü basamak olmadan önce ve üçüncü basamak olduktan sonra acil servis, pediatri kliniği, pediatrik yoğun bakım ünitesi, yenidoğan yoğun bakım ünitesi, doğum salonu, riskli gebelik ve septik servise başvuran sevk edilen veya yatırılarak tedavi edilen hastaların sayıları ve ilaç maliyetleri karşılaştırıldı. Bu çalışmada elde edilen veriler sadece yılında bir ayını (Nisan 2012 ve nisan 2013) içermekte idi. Veriler retrospektif incelendi. Bulgular: Nisan 2012 ve nisan 2013 aylarında ayaktan ve yatarak tedavi edilen hastaların sayısı sırası ile 10838 ve 11066 idi. Nisan 2012'de ilaç maliyet 51515 TL (yaklaşık 25 000 USD) ve nisan 2013'de ise 75552 TL (yaklaşık 37 000 USD) idi. Yatan hastalardan nisan 2012'de 132'si, nisan 2013'de 91'i sevk edildi (p

🔖

Cite This Article

BUCAK, İ. H., BÜLBÜL, M., ÇEVİK, M. Ö., TURGUT, M., ALMİŞ, H. (2022). Öncesi ve Sonrası: Türkiye'de Üçüncü Basamak Bir Hastanenin İlaç Harcamaları. Journal of Clinical and Analytical Medicine, Cilt: 7 - Sayı: 4, 494–496. https://ajindex.com/articles/560850

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Erko Ü, Ağırbaş İ. Cost Analysis in Hospitals and An Application of Activity Based Costing Method. Ankara Üniversitesi Tıp Fakültesi Mecmuası 2011;64(2):87-95.
  2. Özgen H, Tatar M. Cost-Effectiveness Analysis as an Efficiency Evaluation Tech- nique in The Health Sector and the Case of Turkey. Hacettepe Sağlık İdaresi Der- gisi 2007;10(2):109-37.
  3. Ahuja J, Gupta AK, Kohli K. Pharmacoeconomics. Natl Med J India 2004;17(2):80- 3. Ahmad A, Patel I, Parimilakrishnan S, Mohanta GP, Chung H, Chang J. The role of pharmacoeconomics in current Indian healthcare system. J Res Pharm Pract 2013;2(1):3-9.
  4. Cecchini M, Sassi F. Preventing Obesity in the USA: Impact on Health Service Utilization and Costs. Pharmacoeconomics 2015;33(7):765-76.
  5. Coop C, Edlin R, Brown J, Farquhar C. Cost-effectiveness of the New Zea- land diabetes in pregnancy guideline screening recommendations. BMJ Open 2015;5(6):e006996. Ekpu VU, Brown AK. The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence. Tob Use Insights 2015;8:1-35.
  6. Tricco AC, Ashoor HM, Antony J, Beyene J, Veroniki AA, Isaranuwatchai W, et al. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis. BMJ 2014;349:g5459. Domínguez-Ortega J, Phillips-Anglés E, Barranco P, Quirce S. Cost-effectiveness of asthma therapy: a comprehensive review. J Asthma 2015;52(6):529-37.
  7. Brown T, Pilkington G, Bagust A, Boland A, Oyee J, Tudur-Smith C, et al. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic re- view and economic evaluation. Health Technol Assess 2013;17(31):281-2.